Chapters

Transcript

Video

Based on the results/signals observed in OC patients in ARTISTRY-1, how do you design a translationally optimal trial with nemvaleukin to assess its effectives as a monotherapeutic vs. combinatorial agent?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

John L. Hays, MD

John L. Hays, MD

Associate Professor, Department of Internal Medicine
Medical Director of the Clinical Trials Office
The Ohio State University College of Medicine
Wexner Medical Center & James Cancer Hospital
Columbus, OH